Companies /Healthcare

Recursion Pharmaceuticals Inc - Class A

NASDAQ: RXRX Biotechnology
$3.63
▲ $0.19 (+5.52%) today
Markets closed · 8:16pm ET

Q1 2026 Earnings

Reported May 6, 2026, 6:31am ET · SEC source
$-0.22
Beat +14.43%
EPS · est. $-0.26
$6.5M
Miss −58.98%
Revenue · est. $15.8M
−3.9%
Trailing market
RXRX vs S&P since report
1 quarter
Consecutive EPS misses

Market Reaction

% change · around the report
−6%−3%0+3%May 6May 7report 6:31am ETearnings+0.3%−1.9%
−6%−3%0+3%May 6May 7earnings+0.3%−1.9%
RXRX −1.9%S&P 500 +0.3%
−6%−3%0+3%May 6May 7report 6:31am ETearnings+0.5%−1.9%
−6%−3%0+3%May 6May 7earnings+0.5%−1.9%
RXRX −1.9%NASDAQ +0.5%
−5%0+5%+10%May 5May 14report 6:31am ETearnings+1.9%−5.6%
−5%0+5%+10%May 5May 14earnings+1.9%−5.6%
RXRX −5.6%S&P 500 +1.9%
−5%0+5%+10%May 5May 14report 6:31am ETearnings+3.4%−5.6%
−5%0+5%+10%May 5May 14earnings+3.4%−5.6%
RXRX −5.6%NASDAQ +3.4%
+1.78%
Day of report
−4.66%
Next session
−11.08%
One week
−3.21%
30 days

S&P 500 over the same 30 days: +0.73%.

Did RXRX Beat Earnings? Q1 2026 Results

Recursion Pharmaceuticals posted a sobering but incrementally improving first quarter for 2026, with revenue falling sharply to $6.47 million from $14.74 million a year ago while the company's net loss narrowed to $117.50 million, translating to a loss of $0.22 per share. The revenue decline stemmed primarily from reduced Roche collaboration payments as certain prior-period project phases wound down, a structural headwind that weighed on the top line even as the underlying cost structure improved meaningfully. R&D spending dropped to $87.90 million from $129.63 million, in part because the year-ago quarter absorbed $27.10 million in non-cash data acquisition costs, while G&A expenses fell to $34.59 million from $54.65 million. The company ended March with $665.18 million in cash and reiterated guidance for less than $390.00 million in operational cash burn for 2026, projecting runway into early 2028 without additional financing. Adding to the backdrop, founder Chris Gibson's decision not to seek board re-election drew investor attention ahead of the print, though multiple clinical catalysts across REC-4881, REC-1245, and REC-4539 are expected to drive the narrative in the months ahead.

Key Takeaways
  • Operating efficiencies and strategic reprioritization of clinical portfolio reduced cash operating expenses by approximately 30% YoY
  • Lower R&D expenses driven by timing of Tempus record purchases and absence of $27.1M non-cash data expenses from Q1 2025
  • Lower G&A expenses driven by reduced salaries and absence of one-time transaction costs from prior year
  • Revenue decline due to completion of certain Roche project phases in prior period

“We are seeing strong momentum and execution across our portfolio, with increasing evidence that our full stack platform can translate biological and chemical insights into differentiated clinical programs.”

Recursion Pharmaceuticals CEO, on the earnings call

Forward Guidance & Outlook

Recursion reiterates 2026 guidance of less than $390 million in operational cash burn, with cash runway expected to extend into early 2028 without additional financing. The company expects multiple near-term catalysts: REC-4881 regulatory update from FDA engagement in 2H26 with additional clinical data in 1H27; REC-1245 additional Phase 1 dose escalation data in 2H26; go/no-go decisions on IND-enabling studies for REC-7735 and REC-102 in 2H26; early combo safety/PK data for REC-617 in 1H27; early monotherapy data for REC-3565 in 1H27; and early monotherapy safety/PK data for REC-4539 in 2H27. Partnered programs with Sanofi are expected to progress toward development candidate designations, and Roche/Genentech programs are expected to advance toward target validation milestones over the next 12 months.

RXRX YoY Financials

Revenue$6.5M
Operating Income$-128,505,000
Net Income$-117,504,000

Figures from SEC filings and company reports. Not investment advice.